Julia OzięBło
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julia OzięBło has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Magdalena Skrzyniarz
Medical University of Lublin, Lublin, Poland
10 shared publications - Aleksandra Zynkowska
Medical University of Lublin, Lublin, Poland
10 shared publications - Jakub Jakubowski
Medical University of Warsaw, Warsaw, Poland
10 shared publications - Karol Kraska
Medical University of Lublin, Lublin, Poland
10 shared publications - Karolina Klusek
Medical University of Lublin, Poland
10 shared publications - Magdalena Kijowska
Medical University of Lublin, Lublin, Poland
10 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
GLP-1 AGONISTS IN PSYCHIATRY — A NEW THERAPEUTIC DIRECTION FOR DEPRESSION, ADDICTIONS, AND EATING DISORDERS
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the treatment of type 2 diabetes mellitus and obesity, are increasingly being investigated for their potential relevance to psychiatric disorders. Accumulating preclinical and clinical evidence indicates that GLP-1 signaling extends beyond metabolic regulation and may influence central mechanisms implicated in mood regulation, motivational processing, compulsive reward-seeking, and interoceptive control. This review synthesizes current mechanistic, preclinical, clinical, and registry-based evidence concerning the possible role of GLP-1 RAs in psychiatry, with particular emphasis on major depressive disorder, substance use disorders, and eating disorders. The biological rationale for their psychiatric relevance is supported by evidence of GLP-1-mediated signaling through circumventricular organs, vagal–brainstem pathways, and selected central nervous system regions, including hypothalamic, hippocampal, and mesolimbic reward-related circuits. Proposed mechanisms include modulation of reward salience, attenuation of neuroinflammatory signaling, improvement of metabolic-inflammatory burden, and enhancement of neuroplastic processes. The clinical evidence remains heterogeneous and indication-specific. In depression, the most consistent findings relate to cognitive and motivational domains, particularly in patients with major depressive disorder and coexisting overweight or obesity, whereas broader evidence from metabolic trials suggests modest reductions in depressive symptoms without establishing disorder-specific antidepressant efficacy. In substance use disorders, alcohol use disorder currently represents the most advanced area of investigation, with semaglutide demonstrating favorable outcomes in a phase 2 trial, while exenatide showed no overall reduction in heavy drinking but reduced alcohol cue reactivity and suggested potential benefit in obese participants. Evidence for nicotine use disorder is mixed, and data concerning opioid and stimulant use disorders remain preliminary. In eating disorders, binge-eating phenotypes appear to be the most plausible therapeutic target, whereas evidence for bulimia nervosa is limited and anorexia-spectrum disorders raise important safety concerns due to appetite suppression and weight loss. Overall, the safety profile of GLP-1 RAs in psychiatric populations appears broadly consistent with their established metabolic use, with gastrointestinal adverse effects predominating; however, psychiatric monitoring remains advisable because observational safety data are not fully concordant. Current evidence supports further diagnosis-specific randomized controlled trials but does not yet justify routine psychiatric prescribing outside carefully selected clinical contexts or research settings.
- 30 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessGLP-1 AGONISTS IN PSYCHIATRY — A NEW THERAPEUTIC DIRECTION FOR DEPRESSION, ADDICTIONS, AND EATING DISORDERS
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the treatment of type 2 diabetes mellitus and obesity, are increasingly being investigated for their potential relevance to psychiatric disorders. Accumulating preclinical and clinical evidence indicates that GLP-1 signaling extends beyond metabolic regulation and may influence central mechanisms implicated in mood regulation, motivational processing, compulsive reward-seeking, and interoceptive control. This review synthesizes current mechanistic, preclinical, clinical, and registry-based evidence concerning the possible role of GLP-1 RAs in psychiatry, with particular emphasis on major depressive disorder, substance use disorders, and eating disorders. The biological rationale for their psychiatric relevance is supported by evidence of GLP-1-mediated signaling through circumventricular organs, vagal–brainstem pathways, and selected central nervous system regions, including hypothalamic, hippocampal, and mesolimbic reward-related circuits. Proposed mechanisms include modulation of reward salience, attenuation of neuroinflammatory signaling, improvement of metabolic-inflammatory burden, and enhancement of neuroplastic processes. The clinical evidence remains heterogeneous and indication-specific. In depression, the most consistent findings relate to cognitive and motivational domains, particularly in patients with major depressive disorder and coexisting overweight or obesity, whereas broader evidence from metabolic trials suggests modest reductions in depressive symptoms without establishing disorder-specific antidepressant efficacy. In substance use disorders, alcohol use disorder currently represents the most advanced area of investigation, with semaglutide demonstrating favorable outcomes in a phase 2 trial, while exenatide showed no overall reduction in heavy drinking but reduced alcohol cue reactivity and suggested potential benefit in obese participants. Evidence for nicotine use disorder is mixed, and data concerning opioid and stimulant use disorders remain preliminary. In eating disorders, binge-eating phenotypes appear to be the most plausible therapeutic target, whereas evidence for bulimia nervosa is limited and anorexia-spectrum disorders raise important safety concerns due to appetite suppression and weight loss. Overall, the safety profile of GLP-1 RAs in psychiatric populations appears broadly consistent with their established metabolic use, with gastrointestinal adverse effects predominating; however, psychiatric monitoring remains advisable because observational safety data are not fully concordant. Current evidence supports further diagnosis-specific randomized controlled trials but does not yet justify routine psychiatric prescribing outside carefully selected clinical contexts or research settings.
- Open Access
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
OPIOID-FREE AND OPIOID-SPARING ANESTHESIA IN MODERN PERIOPERATIVE CARE — BENEFITS, LIMITATIONS, AND CLINICAL APPLICATIONS
Opioid-free anesthesia (OFA) and opioid-sparing anesthesia (OSA) have emerged from two converging developments in perioperative medicine: first, the need to reduce opioid-related adverse drug events such as postoperative nausea and vomiting (PONV), respiratory depression, ileus, sedation, and possibly persistent postoperative use; and second, the maturation of enhanced recovery pathways built around multimodal, function-oriented analgesia. In contemporary evidence, however, strict elimination of intraoperative opioids has not shown universal superiority over well-conducted opioid-based anesthesia (OBA) for postoperative pain control or 24-hour opioid consumption. The most reproducible benefit of OFA is lower PONV in selected settings, whereas the most important safety signal is regimen-dependent bradycardia and hemodynamic instability, especially in dexmedetomidine-heavy protocols. By contrast, broader OSA strategies, particularly when built on acetaminophen, NSAIDs, regional anesthesia, judicious total intravenous anesthesia (TIVA), and selected adjuvants such as ketamine or lidocaine, are aligned with ERAS and other major perioperative guidance and have the strongest overall clinical support. This narrative review examines definitions, mechanisms, pharmacology, protocols, clinical outcomes, limitations, and practical applications of OFA and OSA in modern perioperative care. Conclusion: contemporary perioperative practice is better supported by individualized opioid stewardship and multimodal opioid-sparing care than by a dogmatic “zero-opioid” rule. OFA remains a reasonable option in selected phenotypes and procedures, but current evidence does not justify its routine use as a default replacement for all opioid-inclusive techniques.
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessOPIOID-FREE AND OPIOID-SPARING ANESTHESIA IN MODERN PERIOPERATIVE CARE — BENEFITS, LIMITATIONS, AND CLINICAL APPLICATIONS
Opioid-free anesthesia (OFA) and opioid-sparing anesthesia (OSA) have emerged from two converging developments in perioperative medicine: first, the need to reduce opioid-related adverse drug events such as postoperative nausea and vomiting (PONV), respiratory depression, ileus, sedation, and possibly persistent postoperative use; and second, the maturation of enhanced recovery pathways built around multimodal, function-oriented analgesia. In contemporary evidence, however, strict elimination of intraoperative opioids has not shown universal superiority over well-conducted opioid-based anesthesia (OBA) for postoperative pain control or 24-hour opioid consumption. The most reproducible benefit of OFA is lower PONV in selected settings, whereas the most important safety signal is regimen-dependent bradycardia and hemodynamic instability, especially in dexmedetomidine-heavy protocols. By contrast, broader OSA strategies, particularly when built on acetaminophen, NSAIDs, regional anesthesia, judicious total intravenous anesthesia (TIVA), and selected adjuvants such as ketamine or lidocaine, are aligned with ERAS and other major perioperative guidance and have the strongest overall clinical support. This narrative review examines definitions, mechanisms, pharmacology, protocols, clinical outcomes, limitations, and practical applications of OFA and OSA in modern perioperative care. Conclusion: contemporary perioperative practice is better supported by individualized opioid stewardship and multimodal opioid-sparing care than by a dogmatic “zero-opioid” rule. OFA remains a reasonable option in selected phenotypes and procedures, but current evidence does not justify its routine use as a default replacement for all opioid-inclusive techniques.
- Open Access
- 24 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
ROLE OF ANTIFIBRINOLYTIC THERAPY IN GYNECOLOGIC SURGERY: TRANEXAMIC ACID FOR REDUCING PERIOPERATIVE BLOOD LOSS
Perioperative hemorrhage remains an important clinical concern in gynecologic surgery, including hysterectomy, myomectomy, cesarean delivery, and oncologic procedures, as excessive blood loss may contribute to postoperative anemia, transfusion requirements, reoperation, prolonged hospitalization, and increased perioperative morbidity. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that reversibly binds to plasminogen and inhibits its conversion to plasmin, thereby reducing fibrin degradation and stabilizing formed clots. This review evaluates current evidence regarding the pharmacological properties, dosing strategies, efficacy, and safety profile of TXA in gynecologic surgical practice. Available randomized controlled trials and meta-analyses indicate that prophylactic administration of TXA, most commonly as a 1 g intravenous dose before surgical incision, significantly reduces intraoperative and postoperative blood loss across several gynecologic procedures. In benign hysterectomy, a large randomized controlled trial involving 332 patients demonstrated that intravenous TXA significantly decreased mean blood loss compared with placebo and reduced the incidence of bleeding exceeding 500 mL, as well as the need for reoperation due to postoperative hemorrhage. Evidence from myomectomy studies similarly suggests a clinically relevant reduction in perioperative blood loss, with meta-analytic data showing an average decrease of approximately 213 mL. In cesarean delivery, pooled data from randomized trials have shown that prophylactic TXA reduces total blood loss, transfusion rates, hemoglobin decline, and the need for additional uterotonic agents in both low- and high-risk patients. Comparable benefits have also been reported in selected gynecologic oncology procedures and after cervical conization. Importantly, across available studies, standard perioperative doses of TXA have not been associated with a significant increase in thromboembolic complications, although careful patient selection remains necessary, particularly in individuals with active thromboembolic disease or severe renal impairment. Overall, current evidence supports TXA as an effective, safe, and cost-efficient adjunct for reducing perioperative bleeding and transfusion requirements in gynecologic surgery. Future research should focus on defining optimal dosing and timing protocols for specific surgical subgroups, including extensive oncologic debulking procedures and complex endometriosis surgery, as well as evaluating long-term safety outcomes.
- 24 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessROLE OF ANTIFIBRINOLYTIC THERAPY IN GYNECOLOGIC SURGERY: TRANEXAMIC ACID FOR REDUCING PERIOPERATIVE BLOOD LOSS
Perioperative hemorrhage remains an important clinical concern in gynecologic surgery, including hysterectomy, myomectomy, cesarean delivery, and oncologic procedures, as excessive blood loss may contribute to postoperative anemia, transfusion requirements, reoperation, prolonged hospitalization, and increased perioperative morbidity. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that reversibly binds to plasminogen and inhibits its conversion to plasmin, thereby reducing fibrin degradation and stabilizing formed clots. This review evaluates current evidence regarding the pharmacological properties, dosing strategies, efficacy, and safety profile of TXA in gynecologic surgical practice. Available randomized controlled trials and meta-analyses indicate that prophylactic administration of TXA, most commonly as a 1 g intravenous dose before surgical incision, significantly reduces intraoperative and postoperative blood loss across several gynecologic procedures. In benign hysterectomy, a large randomized controlled trial involving 332 patients demonstrated that intravenous TXA significantly decreased mean blood loss compared with placebo and reduced the incidence of bleeding exceeding 500 mL, as well as the need for reoperation due to postoperative hemorrhage. Evidence from myomectomy studies similarly suggests a clinically relevant reduction in perioperative blood loss, with meta-analytic data showing an average decrease of approximately 213 mL. In cesarean delivery, pooled data from randomized trials have shown that prophylactic TXA reduces total blood loss, transfusion rates, hemoglobin decline, and the need for additional uterotonic agents in both low- and high-risk patients. Comparable benefits have also been reported in selected gynecologic oncology procedures and after cervical conization. Importantly, across available studies, standard perioperative doses of TXA have not been associated with a significant increase in thromboembolic complications, although careful patient selection remains necessary, particularly in individuals with active thromboembolic disease or severe renal impairment. Overall, current evidence supports TXA as an effective, safe, and cost-efficient adjunct for reducing perioperative bleeding and transfusion requirements in gynecologic surgery. Future research should focus on defining optimal dosing and timing protocols for specific surgical subgroups, including extensive oncologic debulking procedures and complex endometriosis surgery, as well as evaluating long-term safety outcomes.
- Open Access
- 21 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
ADVANCES IN THE DIAGNOSIS AND SURGICAL MANAGEMENT OF CHOLESTEATOMA: A CONTEMPORARY REVIEW
Cholesteatoma is a chronic, locally destructive disease of the middle ear characterized by the presence of keratinizing stratified squamous epithelium within the tympanic cavity and mastoid process. Despite its histologically benign nature, it may lead to the destruction of bony structures, damage to the auditory ossicles, and the development of serious intra- and extracranial complications. Its complex pathogenesis and tendency to recur make cholesteatoma a significant diagnostic and therapeutic challenge. In recent years, substantial progress has been made in both the diagnosis and surgical treatment of cholesteatoma. High-resolution computed tomography and magnetic resonance imaging with non-echo-planar diffusion-weighted imaging (non-EPI DWI) sequences enable accurate assessment of primary, residual, and recurrent lesions. Surgical treatment remains the cornerstone of therapy, while advances in endoscopic techniques have improved visualization of anatomical structures and enhanced surgical effectiveness while reducing invasiveness. Artificial intelligence systems are also gaining increasing importance in supporting imaging analysis, treatment planning, and clinical decision-making. The aim of this review is to present current advances in the diagnosis and surgical management of cholesteatoma, with particular emphasis on modern imaging techniques, endoscopic ear surgery, and applications of artificial intelligence. The development of these technologies may contribute in the future to improved treatment outcomes and reduced risk of disease recurrence.
- 21 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessADVANCES IN THE DIAGNOSIS AND SURGICAL MANAGEMENT OF CHOLESTEATOMA: A CONTEMPORARY REVIEW
Cholesteatoma is a chronic, locally destructive disease of the middle ear characterized by the presence of keratinizing stratified squamous epithelium within the tympanic cavity and mastoid process. Despite its histologically benign nature, it may lead to the destruction of bony structures, damage to the auditory ossicles, and the development of serious intra- and extracranial complications. Its complex pathogenesis and tendency to recur make cholesteatoma a significant diagnostic and therapeutic challenge. In recent years, substantial progress has been made in both the diagnosis and surgical treatment of cholesteatoma. High-resolution computed tomography and magnetic resonance imaging with non-echo-planar diffusion-weighted imaging (non-EPI DWI) sequences enable accurate assessment of primary, residual, and recurrent lesions. Surgical treatment remains the cornerstone of therapy, while advances in endoscopic techniques have improved visualization of anatomical structures and enhanced surgical effectiveness while reducing invasiveness. Artificial intelligence systems are also gaining increasing importance in supporting imaging analysis, treatment planning, and clinical decision-making. The aim of this review is to present current advances in the diagnosis and surgical management of cholesteatoma, with particular emphasis on modern imaging techniques, endoscopic ear surgery, and applications of artificial intelligence. The development of these technologies may contribute in the future to improved treatment outcomes and reduced risk of disease recurrence.
- Open Access
- 20 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
FUTURE PROSPECTS FOR ACNE TREATMENT- ARTIFICIAL INTELLIGENCE, NANOMEDICINE AND PRECISION DERMATOLOGY: A COMPREHENSIVE REVIEW
Acne vulgaris is one of the most common chronic inflammatory skin diseases with a complex and multifactorial pathogenesis, including keratinization disorders, excessive sebum production, skin microbiome dysbiosis, inflammatory processes, and hormonal and genetic factors. Despite the availability of numerous effective therapies, such as retinoids, antibiotics, and hormonal therapy, their use is still associated with limitations, including adverse effects, unsatisfactory results, the risk of antibiotic resistance, and disease recurrence. Consequently, contemporary dermatology is increasingly focusing on the development of personalized therapies and modern technologies supporting the diagnosis and treatment of acne. The aim of this study was to review current trends in the diagnosis and treatment of acne vulgaris, which are aimed at combining digital and biotechnological tools and exploring new treatment alternatives to improve treatment effectiveness. Data were analyzed regarding the use of artificial intelligence algorithms in assessing skin lesions, the use of nanocarriers in drug delivery, and the importance of genetic, immunological, hormonal, and microbiological factors in the pathogenesis of acne. The complex and multifactorial nature of acne vulgaris pathogenesis suggests that effective future therapies will require a multifaceted approach that takes into account individual patient predispositions.
- 20 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessFUTURE PROSPECTS FOR ACNE TREATMENT- ARTIFICIAL INTELLIGENCE, NANOMEDICINE AND PRECISION DERMATOLOGY: A COMPREHENSIVE REVIEW
Acne vulgaris is one of the most common chronic inflammatory skin diseases with a complex and multifactorial pathogenesis, including keratinization disorders, excessive sebum production, skin microbiome dysbiosis, inflammatory processes, and hormonal and genetic factors. Despite the availability of numerous effective therapies, such as retinoids, antibiotics, and hormonal therapy, their use is still associated with limitations, including adverse effects, unsatisfactory results, the risk of antibiotic resistance, and disease recurrence. Consequently, contemporary dermatology is increasingly focusing on the development of personalized therapies and modern technologies supporting the diagnosis and treatment of acne. The aim of this study was to review current trends in the diagnosis and treatment of acne vulgaris, which are aimed at combining digital and biotechnological tools and exploring new treatment alternatives to improve treatment effectiveness. Data were analyzed regarding the use of artificial intelligence algorithms in assessing skin lesions, the use of nanocarriers in drug delivery, and the importance of genetic, immunological, hormonal, and microbiological factors in the pathogenesis of acne. The complex and multifactorial nature of acne vulgaris pathogenesis suggests that effective future therapies will require a multifaceted approach that takes into account individual patient predispositions.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
PREMENSTRUAL DYSPHORIC DISORDER (PMDD): CURRENT PHARMACOTHERAPY AND EMERGING TREATMENT APPROACHES
Premenstrual dysphoric disorder (PMDD) is a cyclic mood disorder affecting a subset of women in the late luteal phase, marked by severe affective and physical symptoms that resolve with menses. It is distinguished from milder premenstrual syndrome (PMS) by symptom severity and functional impairment. PMDD causes substantial distress: women with PMDD have functional impairments comparable to other depressive disorders and increased work absences, and PMDD is associated with higher rates of suicidal ideation and attempts. First-line pharmacotherapy consists of selective serotonin reuptake inhibitors (SSRIs) and hormone-based treatments. SSRIs (e.g. sertraline, fluoxetine, paroxetine, escitalopram) are effective when dosed continuously or in the luteal phase, often producing rapid symptom relief at low doses. Hormonal therapies (e.g. combined oral contraceptives with drospirenone/ethinyl estradiol, GnRH agonists with add-back) can mitigate symptoms by suppressing cyclic ovarian hormone fluctuations. Emerging treatments target PMDD’s neuroendocrine underpinnings: for example, sepranolone (an allopregnanolone antagonist) has shown promising early results. Novel approaches under investigation include neurosteroid modulators, anti-inflammatory strategies, and personalized interventions (genetic or biomarker-driven therapy). This review summarizes current evidence-based pharmacotherapies for PMDD and discusses emerging treatment avenues based on advances in PMDD neurobiology and psychoneuroendocrinology.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessPREMENSTRUAL DYSPHORIC DISORDER (PMDD): CURRENT PHARMACOTHERAPY AND EMERGING TREATMENT APPROACHES
Premenstrual dysphoric disorder (PMDD) is a cyclic mood disorder affecting a subset of women in the late luteal phase, marked by severe affective and physical symptoms that resolve with menses. It is distinguished from milder premenstrual syndrome (PMS) by symptom severity and functional impairment. PMDD causes substantial distress: women with PMDD have functional impairments comparable to other depressive disorders and increased work absences, and PMDD is associated with higher rates of suicidal ideation and attempts. First-line pharmacotherapy consists of selective serotonin reuptake inhibitors (SSRIs) and hormone-based treatments. SSRIs (e.g. sertraline, fluoxetine, paroxetine, escitalopram) are effective when dosed continuously or in the luteal phase, often producing rapid symptom relief at low doses. Hormonal therapies (e.g. combined oral contraceptives with drospirenone/ethinyl estradiol, GnRH agonists with add-back) can mitigate symptoms by suppressing cyclic ovarian hormone fluctuations. Emerging treatments target PMDD’s neuroendocrine underpinnings: for example, sepranolone (an allopregnanolone antagonist) has shown promising early results. Novel approaches under investigation include neurosteroid modulators, anti-inflammatory strategies, and personalized interventions (genetic or biomarker-driven therapy). This review summarizes current evidence-based pharmacotherapies for PMDD and discusses emerging treatment avenues based on advances in PMDD neurobiology and psychoneuroendocrinology.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
THE ROLE OF ELECTROCARDIOGRAPHY IN THE DIAGNOSIS AND MONITORING OF FABRY DISEASE: A COMPREHENSIVE REVIEW
Anderson-Fabry disease (FD) is a rare, X-linked lysosomal storage disorder in which the progressive accumulation of globotriaosylceramide (Gb3) leads to widespread multi-organ damage, with cardiac involvement serving as the primary cause of mortality. This comprehensive review aims to summarize the current state of knowledge regarding the clinical application of electrocardiography (ECG) as a pivotal and cost-effective tool in the management of patients with FD. The paper systematically categorizes ECG findings across the various stages of the disease's progression. Early stages are typically characterized by a shortened PR interval and increased QRS complex voltages, which frequently manifest prior to the development of structural changes identifiable through echocardiography. In the more advanced stages of the disease, the predominant features include signs of left ventricular hypertrophy (LVH), ST-segment depressions, and deep T-wave inversions, which often mimic the presentation of hypertrophic cardiomyopathy or myocardial ischemia. Furthermore, this review discusses the evolution of conduction disturbances, including atrioventricular blocks and atrial fibrillation, while emphasizing the absolute necessity of Holter monitoring for effective arrhythmia risk stratification. The impact of enzyme replacement therapy (ERT) on the stabilization of ECG patterns is evaluated, indicating that early clinical intervention is crucial for the prevention of irreversible electrical remodeling. In conclusion, despite the ongoing development of advanced imaging modalities, the standard 12-lead ECG remains a fundamental and indispensable tool that shortens the diagnostic odyssey and allows for the precise monitoring of treatment efficacy in Fabry disease.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessTHE ROLE OF ELECTROCARDIOGRAPHY IN THE DIAGNOSIS AND MONITORING OF FABRY DISEASE: A COMPREHENSIVE REVIEW
Anderson-Fabry disease (FD) is a rare, X-linked lysosomal storage disorder in which the progressive accumulation of globotriaosylceramide (Gb3) leads to widespread multi-organ damage, with cardiac involvement serving as the primary cause of mortality. This comprehensive review aims to summarize the current state of knowledge regarding the clinical application of electrocardiography (ECG) as a pivotal and cost-effective tool in the management of patients with FD. The paper systematically categorizes ECG findings across the various stages of the disease's progression. Early stages are typically characterized by a shortened PR interval and increased QRS complex voltages, which frequently manifest prior to the development of structural changes identifiable through echocardiography. In the more advanced stages of the disease, the predominant features include signs of left ventricular hypertrophy (LVH), ST-segment depressions, and deep T-wave inversions, which often mimic the presentation of hypertrophic cardiomyopathy or myocardial ischemia. Furthermore, this review discusses the evolution of conduction disturbances, including atrioventricular blocks and atrial fibrillation, while emphasizing the absolute necessity of Holter monitoring for effective arrhythmia risk stratification. The impact of enzyme replacement therapy (ERT) on the stabilization of ECG patterns is evaluated, indicating that early clinical intervention is crucial for the prevention of irreversible electrical remodeling. In conclusion, despite the ongoing development of advanced imaging modalities, the standard 12-lead ECG remains a fundamental and indispensable tool that shortens the diagnostic odyssey and allows for the precise monitoring of treatment efficacy in Fabry disease.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
IMMUNOPATHOGENESIS OF OCULAR MANIFESTATIONS OF GRANULOMATOSIS WITH POLYANGIITIS AND POTENTIAL TARGETS FOR NOVEL BIOLOGICAL THERAPIES
Granulomatosis with polyangiitis (GPA) is a phenotypically heterogeneous form of ANCA-associated vasculitis characterized by two partially overlapping processes: extravascular granulomatous inflammation and necrotizing vasculitis of small- and medium-sized vessels. This dual pathobiology is particularly relevant in ocular disease, where some manifestations primarily reflect active vasculopathy and endothelial injury, whereas others result from locally destructive granulomatous inflammation extending from the sinonasal tract, orbit, sclera, and ocular adnexa. Ocular involvement is reported in approximately one quarter to one third of patients in contemporary pooled analyses, with higher rates in ophthalmology-based cohorts and in head-and-neck–limited disease. The most common manifestations include scleritis, episcleritis, orbital inflammatory mass or pseudotumor, peripheral ulcerative keratitis, and lacrimal system involvement; optic neuropathy, retinochoroidal inflammation, and visual loss are less frequent but potentially sight-threatening. The immunopathogenesis of ophthalmic GPA involves dysregulated B- and T-cell responses, ANCA-mediated neutrophil activation, neutrophil extracellular trap formation, complement amplification, and local tissue-destructive programs mediated by macrophages, plasma cells, fibroblasts, and matrix metalloproteinases. Rituximab remains the best-established biologic therapy, particularly for vasculitic ocular manifestations and peripheral ulcerative keratitis, although granulomatous orbital lesions may be relatively treatment-resistant. Future therapeutic strategies should target BAFF/APRIL/BCMA/TACI signaling, CD38-positive plasma cells, IL-6/IL-6R, IL-21/Tfh/ICOS pathways, Th17/IL-23 signaling, C5a/C5aR-mediated complement activation, NETosis, and monocyte-driven tissue invasion. A layered therapeutic approach combining control of ANCA-dependent inflammation with suppression of local granulomatous tissue destruction may be especially promising, although ocular-specific randomized trials remain lacking.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessIMMUNOPATHOGENESIS OF OCULAR MANIFESTATIONS OF GRANULOMATOSIS WITH POLYANGIITIS AND POTENTIAL TARGETS FOR NOVEL BIOLOGICAL THERAPIES
Granulomatosis with polyangiitis (GPA) is a phenotypically heterogeneous form of ANCA-associated vasculitis characterized by two partially overlapping processes: extravascular granulomatous inflammation and necrotizing vasculitis of small- and medium-sized vessels. This dual pathobiology is particularly relevant in ocular disease, where some manifestations primarily reflect active vasculopathy and endothelial injury, whereas others result from locally destructive granulomatous inflammation extending from the sinonasal tract, orbit, sclera, and ocular adnexa. Ocular involvement is reported in approximately one quarter to one third of patients in contemporary pooled analyses, with higher rates in ophthalmology-based cohorts and in head-and-neck–limited disease. The most common manifestations include scleritis, episcleritis, orbital inflammatory mass or pseudotumor, peripheral ulcerative keratitis, and lacrimal system involvement; optic neuropathy, retinochoroidal inflammation, and visual loss are less frequent but potentially sight-threatening. The immunopathogenesis of ophthalmic GPA involves dysregulated B- and T-cell responses, ANCA-mediated neutrophil activation, neutrophil extracellular trap formation, complement amplification, and local tissue-destructive programs mediated by macrophages, plasma cells, fibroblasts, and matrix metalloproteinases. Rituximab remains the best-established biologic therapy, particularly for vasculitic ocular manifestations and peripheral ulcerative keratitis, although granulomatous orbital lesions may be relatively treatment-resistant. Future therapeutic strategies should target BAFF/APRIL/BCMA/TACI signaling, CD38-positive plasma cells, IL-6/IL-6R, IL-21/Tfh/ICOS pathways, Th17/IL-23 signaling, C5a/C5aR-mediated complement activation, NETosis, and monocyte-driven tissue invasion. A layered therapeutic approach combining control of ANCA-dependent inflammation with suppression of local granulomatous tissue destruction may be especially promising, although ocular-specific randomized trials remain lacking.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
COMPARATIVE CLINICAL OUTCOMES OF FARICIMAB VERSUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: A FOCUSED REVIEW
This manuscript presents a focused narrative review with systematic literature identification of comparative evidence on faricimab versus aflibercept in adults with diabetic macular edema. The review prioritized randomized phase III evidence and selected only clinically decisive extension, post hoc, and real-world studies published from 2022 through 2025. The predefined PICO was: adults with DME; intervention faricimab; comparator aflibercept; outcomes best-corrected visual acuity, central subfield thickness, injection burden and durability, and safety. The core evidence base consisted of the YOSEMITE and RHINE randomized trials and their 2-year follow-up, supplemented by FDA regulatory documents and a small number of directly relevant post hoc and real-world studies. At year 1, faricimab achieved noninferior visual gains versus aflibercept in both trials, with numerically greater reductions in central subfield thickness. At year 2, visual acuity remained comparable, whereas anatomic outcomes and durability continued to favor faricimab, especially in the treat-and-extend arm, in which more than 60% of patients were on every-16-week dosing and approximately 80% were on every-12-week-or-longer dosing by week 96. Safety was broadly similar across randomized arms, although postmarketing retinal vasculitis warnings require continued pharmacovigilance. Direct real-world head-to-head evidence remained sparse; available switch studies suggest benefit primarily in selected aflibercept-refractory eyes. Overall, the present evidence supports faricimab as a clinically relevant alternative to aflibercept in DME when durability and anatomic control are prioritized, but not as a superior agent for letter gain alone.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessCOMPARATIVE CLINICAL OUTCOMES OF FARICIMAB VERSUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: A FOCUSED REVIEW
This manuscript presents a focused narrative review with systematic literature identification of comparative evidence on faricimab versus aflibercept in adults with diabetic macular edema. The review prioritized randomized phase III evidence and selected only clinically decisive extension, post hoc, and real-world studies published from 2022 through 2025. The predefined PICO was: adults with DME; intervention faricimab; comparator aflibercept; outcomes best-corrected visual acuity, central subfield thickness, injection burden and durability, and safety. The core evidence base consisted of the YOSEMITE and RHINE randomized trials and their 2-year follow-up, supplemented by FDA regulatory documents and a small number of directly relevant post hoc and real-world studies. At year 1, faricimab achieved noninferior visual gains versus aflibercept in both trials, with numerically greater reductions in central subfield thickness. At year 2, visual acuity remained comparable, whereas anatomic outcomes and durability continued to favor faricimab, especially in the treat-and-extend arm, in which more than 60% of patients were on every-16-week dosing and approximately 80% were on every-12-week-or-longer dosing by week 96. Safety was broadly similar across randomized arms, although postmarketing retinal vasculitis warnings require continued pharmacovigilance. Direct real-world head-to-head evidence remained sparse; available switch studies suggest benefit primarily in selected aflibercept-refractory eyes. Overall, the present evidence supports faricimab as a clinically relevant alternative to aflibercept in DME when durability and anatomic control are prioritized, but not as a superior agent for letter gain alone.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
ADVANCED BIOMATERIAL PLATFORMS FOR CHRONIC WOUND CARE: SMART DRESSINGS, 3D BIOPRINTING, AND 4D RESPONSIVE TECHNOLOGIES
Chronic non-healing wounds constitute a significant health concern and impose a substantial financial burden on healthcare systems. This creates a pressing need for advanced solutions capable of improving therapeutic efficacy. The aim of this review article is to analyze the current state of knowledge regarding the application of smart dressings and 3D and 4D bioprinting technologies in the treatment of chronic wounds. The methodology was based on a critical review and synthesis of scientific literature in the fields of biomaterials engineering and regenerative medicine. Contemporary hydrogel-based matrices integrated with biosensors and machine learning algorithms effectively transform passive mechanical wound protection into an automated system for monitoring the wound microenvironment and actively responding to its changes. Concurrently, 3D bioprinting techniques enable precise architectural reconstruction of tissues and the fabrication of grafts tailored to the unique size, shape, and depth of individual injuries. Although smart dressing technologies, 3D and 4D bioprinting are undergoing intensive development, additional preclinical and clinical studies are required to establish their safety and efficacy profiles, which is a prerequisite for the development of national regulatory standards.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessADVANCED BIOMATERIAL PLATFORMS FOR CHRONIC WOUND CARE: SMART DRESSINGS, 3D BIOPRINTING, AND 4D RESPONSIVE TECHNOLOGIES
Chronic non-healing wounds constitute a significant health concern and impose a substantial financial burden on healthcare systems. This creates a pressing need for advanced solutions capable of improving therapeutic efficacy. The aim of this review article is to analyze the current state of knowledge regarding the application of smart dressings and 3D and 4D bioprinting technologies in the treatment of chronic wounds. The methodology was based on a critical review and synthesis of scientific literature in the fields of biomaterials engineering and regenerative medicine. Contemporary hydrogel-based matrices integrated with biosensors and machine learning algorithms effectively transform passive mechanical wound protection into an automated system for monitoring the wound microenvironment and actively responding to its changes. Concurrently, 3D bioprinting techniques enable precise architectural reconstruction of tissues and the fabrication of grafts tailored to the unique size, shape, and depth of individual injuries. Although smart dressing technologies, 3D and 4D bioprinting are undergoing intensive development, additional preclinical and clinical studies are required to establish their safety and efficacy profiles, which is a prerequisite for the development of national regulatory standards.